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Vasopeptidase inhibition: A new treatment approach for endo- of potent paracrine mediators such as nitric oxide (NO),
thelial dysfunction. Angiotensin-converting enzyme (ACE) in- angiotensin II, and endothelin-1 (Fig. 1). The different
hibition is a well-established principle in the treatment of endo- circulating and local systems show important synergismsthelial dysfunction. Numerous preclinical and clinical studies
and interactions. They may either have synergistic effectshave clearly demonstrated the beneficial effects of inhibiting
or may be the functional counterpart of another systemthe renin-angiotensin-aldosterone system (RAS) in states of im-
paired endothelial function. The successful use of ACE inhibi- in a subtle multivariate balance. As such, atrial natriuretic
tors encouraged attempts to inhibit other key enzymes in the peptides (ANP) counteract the effects of angiotensin II.
regulation of vascular tone, such as the neutral endopeptidase
Since effects of endothelium-derived substances are not(NEP). Similar to ACE, NEP is an endothelial cell surface metal-
limited to vasoconstriction or vasodilatation, but may alsoloproteinase that is involved in the degradation of several regu-
latory peptides, including the natriuretic peptides, and, thus, include regulation of mitogenesis, endothelial dysfunc-
NEP inhibition augments vasodilatation and natriuresis through tion not only affects the function of the cardiovascular
increased levels of atrial natriuretic peptide (ANP). By inhib- system, but also its structure. In fact, some endothelial
iting the RAS and potentiating the natriuretic peptide system
substances stimulate the production of cytokines andat the same time, combined NEP/ACE inhibitors, the so-called
growth factors, leading to vascular smooth muscle cellvasopeptidase inhibitors, reduce vasoconstriction and enhance
vasodilatation, thereby decreasing peripheral vascular resis- proliferation. Thus, the balance of vasoactive peptides
tance and blood pressure. Within the vessel wall this may lead to warrants an appropriate adaptation of vascular tone and
a reduction of vasoconstrictor and proliferative mediators, such regulates oxidative, proliferative, and inflammatory pro-as angiotensin II and endothelin-1, and may increase local
cesses (Fig. 1). Therefore, the maintenance of the subtlelevels of bradykinin as well as natriuretic peptides. Even though
first results of both preclinical and clinical studies indicate endothelial balance is crucial for the prevention and
that combined inhibition of ACE and NEP by vasopeptidase treatment of cardiovascular disease.
inhibitors represents a promising strategy in the treatment of
hypertension and heart failure, angioedema occurs more fre-
quently on vasopeptidase inhibition as compared to ACE inhi- ACE INHIBITION AND NEP INHIBITION:
bition. To establish vasopeptidase inhibition as a novel option THE COMPONENTS OFin the treatment of cardiovascular disease, further validation
VASOPEPTIDASE INHIBITIONof efficacy and safety of this promising therapeutic principle
is mandatory. The beneficial effect of ACE inhibition has been docu-
mented in many large randomized trials for the treatment
of hypertension [2], after myocardial infarction, and in
The importance of the renin-angiotensin-aldosterone heart failure. The Heart Outcomes Prevention Evalua-
system (RAS) in the pathophysiology of endothelial dys- tion (HOPE) study confirmed that ACE inhibitors are
function, which represents an early stage of cardiovascu- vasoprotective, independent of their effects on blood
lar damage, is illustrated by numerous trials which dem- pressure and remodeling [3]. In addition, in patients with
onstrate improvement of endothelial function [1], and coronary artery disease, improvement of endothelial
even reduction of clinical end points, using agents that function by ACE inhibition could be demonstrated angi-
interrupt this system. The RAS plays a crucial role in ographically in the Trial on Reversing Endothelial Dys-
cardiovascular regulation both as a circulating and para- function (TREND), particularly in patients with high
crine local vascular system. The endothelium is a source serum cholesterol who are prone to severe endothelial
dysfunction [1]. The mechanisms involved may be re-
lated to inhibitory effects on angiotensin formationKey words: vasopeptidase, endothelial dysfunction, ACE inhibition,
hypertension. and/or on activation of bradykinin-related effects. ACE
inhibitors not only prevent the formation of a potent 2003 by the International Society of Nephrology
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Fig. 1. Balance of endothelial function: in-
fluence of simultaneous inhibition of angio-
tensin-converting enzyme (ACE) and neutral
endopeptidase (NEP) by vasopeptidase inhib-
itors (VPI) on production and degradation of
vasoactive peptides. Abbreviations are: ET-1,
endothelin-1; ECE, endothelin converting en-
zyme, ANP, atrial natriuretic peptide; CNP,
C-type natriuretic peptide; NOS, nitric oxide
synthase; Arg, arginine; PLC, phospholipase
C; GC, guanylate cyclase; EC, endothelial cell;
VSMC, vascular smooth muscle cell.
vasoconstrictor with proliferative properties, but also in- including renovascular hypertension, spontaneous hy-
crease the local concentration of bradykinin. In turn, the pertension [4, 5], deoxycorticosterone acetate-induced
production of NO and prostacyclin, which may contrib- hypertension [5], as well as salt-sensitive hypertension
ute to the vascular protective effects of ACE inhibitors [6, 7]. In spontaneously hypertensive rats, vasopeptidase
by vasopeptidase inhibition, by improving local blood inhibition significantly lowered blood pressure, even
flow, and preventing platelet activation. As a principle when combined with experimental diabetes [4]. Since
of vasopeptidase inhibition, beneficial effects of ACE antihypertensive effects of combined ACE/NEP inhibi-
inhibition are combined with the additional inhibition tion exceeded those of ACE inhibition alone, and re-
of the neutral endopeptidase (NEP). sulted in additional improvement of endothelial function
Selective NEP inhibition prevents the degradation of to a greater extent than attributable to lowering of blood
vasoactive peptides such as ANP, BNP, CNP, substance pressure [6, 8], vasopeptidase inhibition may advance as
P, and bradykinin, and increases their biologic activity. a promising novel option for the treatment of various
This implicates that simultaneous inhibition of ACE and forms of hypertension.
NEP may exceed the effects of inhibiting either system In salt-sensitive Dahl rats omapatrilat, as compared
alone. Therefore, compounds with the capability of in- with equipotent doses of the ACE inhibitor captopril,
hibiting ACE and NEP at the same time may offer the restored the impaired NO system by increasing protein
possibility to inhibit the RAS and to potentiate the natri- levels of endothelial NO synthase and vascular nitrate
uretic peptide system by the use of one single molecule,
levels, and normalized endothelium-dependent relax-and, thus, may simultaneously reduce vasoconstriction
ations [6]. Since endothelial dysfunction is not only theand enhance vasodilatation. Correspondingly, a number
result, but also initiator as well as promoter of cardiovas-of substances with affinities for both ACE and NEP are
cular disease, vasopeptidase inhibition may be beneficialcurrently under development. Among those so-called
in interrupting the vicious cycle of altered endothelial“vasopeptidase inhibitors,” omapatrilat is the compound
function.for which most preclinical and clinical data are presently
available.
VASOPEPTIDASE INHIBITORS IN THE
TREATMENT OF HYPERTENSIONVASOPEPTIDASE INHIBITORS IN
EXPERIMENTAL HYPERTENSION Vasopeptidase inhibitors have been shown to be well-
tolerated and effective in clinical trials on hypertensiveVasopeptidase inhibition has been shown to lower
blood pressure under various experimental conditions, patients under several conditions. In 63 patients with
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salt-sensitive hypertension, 40 mg/day of omapatrilat re- The plasma concentrations of omapatrilat administered
vealed a greater reduction in systolic, diastolic, and in to 29 patients with moderate to severe renal impairment,
mean arterial pressure as compared to 20 mg/day of and even in patients on hemodialysis treatment, did not
lisinopril [9]. In a study on 690 patients with mild to differ between the control and those patients with nor-
moderate hypertension, omapatrilat (5 to 40 mg/day) mal renal function [13]. Therefore, no dose adjustment
lowered systolic blood pressure (sBP) a much greater of omapatrilat is required in patients with renal impair-
extent than lisinopril (20 to 40 mg/day). However, com- ment, independent of its severity. In addition, even in
pared with studies of other antihypertensive drugs, such patients with impaired renal function, omapatrilat in-
as ACE inhibitors, the number of patients treated with creased urinary ANP excretion [14, 15], indicating the
vasopeptidase inhibitors at present is rather small. presence of its beneficial properties irrespective of the
Therefore, a large-scale clinical trial with 12,600 pa- degree of renal impairment.
tients, Omapatrilat in Persons with Enhanced Risk of
Atherosclerosis (OPERA), was initiated to evaluate the
SAFETY OF VASOPEPTIDASE INHIBITORSimpact of vasopeptidase inhibition in isolated systolic
hypertension [10]. Patients older than 65 years with sBP Vasopeptidase inhibitors have been used over a broad
between 140 and 160 mm Hg will be randomized in 900 range of dosages, but the number of patients treated
centers to receive either 40 mg/day of omapatrilat or and documented at present is still rather low. In clinical
placebo, and cardiovascular morbidity and mortality will studies, side effects were comparable to those of ACE
be followed up for 3 to 5 years. Another clinical trial with inhibitors. Cough and flush in 573 patients in the Inhibi-
25,267 hypertensive patients, the Omapatrilat Cardiovas- tion of Metalloproteinase in a Randomized Exercise and
cular Treatment Assessment Versus Enalapril (OCTAVE) Symptoms Study in Heart Failure (IMPRESS) trial were
trial, to assess the efficacy and safety of low doses (10 reported to occur equally often with ACE inhibitor treat-
mg/day) of omapatrilat versus 5 mg/day of enalapril has ment [16]. Similarity of adverse effects of ACE inhibition
recently been completed and preliminary results were and vasopeptidase inhibition were recently confirmed in
presented in March 2002. These data indicate that in all 5770 patients in the Omapatrilat Versus Enalapril Ran-
subgroups, omapatrilat was capable of lowering sBP and domized Trial of Utility in Reducing Events (OVER-
dBP after 8 and 24 weeks of treatment, respectively, to TURE) trial [17]. Nevertheless, in data submitted for
a greater extent when compared to enalapril. the new drug application of omapatrilat to the US Food
and Drug Administration (FDA), 44 instances of angi-
oedema were reported among more than 6600 patientsVASOPEPTIDASE INHIBITORS AND
[18]. Therefore, the incidence of angioedema reportedTHE KIDNEY
in the Heart Outcomes Prevention Evaluation (HOPE)Because inhibition of ANP degradation seems to be
study [3] was about twice as high (0.7%) as on treatmentone of the most important features of vasopeptidase
with ramipril. Since patients in the IMPRESS andinhibitors, and elevation of plasma ANP levels by vaso-
OVERTURE trial were pretreated with ACE inhibitors,peptidase inhibition has been demonstrated in several
elevated incidence of angioedema after the onset of vaso-preclinical [6] and clinical studies, there is a strong link
peptidase inhibition requires even more careful evalua-to renal involvement in the regulatory processes induced
tion in large scale, randomized, double-blind clinical tri-by vasopeptidase inhibition.
als. The OCTAVE study was especially designed toSince renal protection, such as in diabetic nephropa-
evaluate the risk of adverse effects on omapatrilat treat-thy, is one of the favorable effects of ACE inhibitors, the
ment in low doses. Preliminary data of the OCTAVEinfluence of vasopeptidase inhibitors on renal function is
study released in March 2002 indicate that in the treat-of major interest. In experimental diabetes, vasopepti-
ment of hypertension, omapatrilat is indeed efficient anddase inhibition reduced albuminuria and led to improve-
safe. Although all other adverse effects occurred withment of renal function [4]. In 89 patients with impaired
comparable frequency, angioedema presented with arenal function (creatinine clearance 60 mL/min), 12
threefold higher incidence in patients treated with a va-weeks treatment with omapatrilat reduced proteinuria
sopeptidase inhibitior as compared to patients on ACEby about 20% and increased serum creatinine by about
inhibitors (2.17% vs. 0.68%, respectively). Thus, an in-15%, thus indicating improvement of renal function by
creased incidence of angioedema appears to be associ-vasopeptidase inhibition. Meanwhile, vasopeptidase in-
ated with simultaneous inhibition of NEP and ACE, andhibition has been proven to slow the progression of renal
it may be speculated that its occurrence is linked toinjury in subtotally nephrectomized rats [11, 12].
the decreased degradation of bradykinin. Since patientsSince renal impairment is a frequent condition among
were treated for 24 weeks only in the OCTAVE study,patients with advanced cardiovascular disease, safety of
pharmacotherapy in these patients is an important issue. safety of vasopeptidase inhibitors remains a matter of
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